A Japanese biscuit is a confectionery delight, more related to a crisp American cookie than a buttery base for southern-style gravy. Whether layered with chocolate, shaped into artistic designs or flavored with matcha or azuki, Japanese biscuits share a key ingredient – more than 90 percent are made with U.S. Western White (WW) wheat, a blend of U.S. soft white (SW) and white club (WC) wheat.
To better understand how U.S. wheat farmers safely grow the high-quality wheat they need, delegates from the Japan Biscuit Association (JBA) visited the Pacific Northwest in October. The trade delegation was organized by U.S. Wheat Associates (USW) with support from the Washington Grain Commission, the Idaho Wheat Commission and the Oregon Wheat Commission.
“Any growth in Japanese biscuit sales means direct growth in the sales of U.S. WW wheat,” said Rick Nakano, USW country director in Japan. “Since U.S. WW wheat has almost exclusive market share of the Japanese confectionery market, we wanted these manufacturers to learn more about U.S. wheat production and quality, including how U.S. farmers use conservation-minded, sustainable farm practices.”
Connecting Customers with the U.S. Wheat Supply Chain
A highlight was the team’s direct engagement with dedicated family farmers, whose commitment defines U.S. wheat quality. In Washington, the team toured Washington State University’s research greenhouse and visited WGC Commissioner Art Schultheis’s fields near Pullman. In Idaho, Commissioner Cliff Tacke’s family hosted a farm tour and lunch, letting the team ask questions and see their farming practices firsthand.
The mission also provided insights into the highly efficient U.S. grain supply chain and logistics. The delegation visited the HighLine Grain Growers Shuttle Loading Facility, the Lewis-Clark Terminal (the largest grain storage facility on the inland river system) and the Lower Granite Dam, underscoring the vital role the Columbia-Snake River system plays in delivering wheat safely and on time to global customers.
To reinforce U.S. quality and safety standards, the team also toured the OMIC laboratory and TEMCO Kalama terminal. There, they saw how each shipment undergoes strict testing, including chemical residue analysis, to ensure U.S. wheat meets or exceeds Japanese specifications.
“The JBA team members expressed their gratitude for the opportunity to look over the entire supply chain from farms to export,” Nakano said. “They found that U.S. wheat is grown by good and passionate family growers with safe farm practices and the harvested wheat is handled by efficient transportation, followed by strict testing of quality.”
The comprehensive trade mission successfully closed the loop for the JBA executives, linking the soft and mellow taste of their final product back to the dedication of the U.S. family farm. This deepened understanding of the safety, quality and reliability of the U.S. wheat supply chain will further support JBA members in expanding their biscuit offerings, directly fueling the continued growth of U.S. wheat exports to Japan.
Fewer cycles of platinum-based chemotherapy improved patient-reported outcomes (PROs) vs a longer duration of therapy prior to maintenance avelumab (Bavencio) without compromising treatment efficacy in patients with advanced urothelial cancer, according to findings from the phase 2 DISCUS trial (NCT06892860) presented during the 2025 ESMO Congress.1
Data from the study demonstrated that patients who received 3 cycles of chemotherapy (n = 98) experienced a mean change in The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) global health status/quality of life (QOL) score of 0.0 (95% CI, –5.0-5.2) compared with –8.5 (95% CI, –14.1 to –2.9) among those who received 6 cycles (n = 104). The difference of 8.5 (95% CI, 0.7-16.3; P = .016) significantly favored the 3-cycle arm, meeting the primary end point of the study. Notably, no difference for time to deterioration in global health status/QOL score was observed between groups based on EORTC QLQ-C30 outcomes (HR 0.81, 95% CI 0.46-1.43).
“More patients [who received] 3 cycles of platinum-based chemotherapy went on to receive maintenance avelumab, which may facilitate long-term efficacy,” Enrique Grande, MD, the director of the Department of Medical Oncology at Quirónsalud in Madrid, Spain, and an adjunct professor at the University of Texas MD Anderson Cancer Center in Houston, said during the presentation. “The most important highlight coming from the DISCUS trial is that we can explore the need for [fewer] cycles of combination [chemotherapy] in the era of antibody-drug conjugates in metastatic urothelial cancer.”
Phase 2 DISCUS Trial: Key Takeaways
The phase 2 DISCUS trial evaluated 3 vs 6 cycles of combination platinum-based chemotherapy prior to maintenance avelumab for the treatment of patients with advanced urothelial cancer.
Patients who received 3 cycles experienced a significant difference of 8.5 points (95% CI, 0.7-16.3; P = .016) vs 6 cycles in terms of EORTC QLQ-C30 global health/QOL scores.
Patients who received 3 cycles experienced similar OS, PFS, and response outcomes compared with those who received 6 cycles.
How was the DISCUS trial designed?
DISCUS was an adaptive, open-label study that enrolled patients with locally advanced or metastatic urothelial cancer who were eligible for any platinum-based chemotherapy.1,2 Patients needed to have not received any prior systemic therapy for metastatic disease, have an ECOG performance statis of 0 to 2, and have no contraindications for immunotherapy. Other key eligibility criteria included being at least 18 years old, having measurable disease per RECIST 1.1 criteria, and having adequate hematologic and organ function.2
Eligible patients were randomly assigned 1:1 to receive 3 or 6 cycles of gemcitabine plus cisplatin/carboplatin.1 Patients in both arms also received maintenance therapy with avelumab for up to 2 years. Stratification occurred based on investigators’ choice of frontline chemotherapy (cisplatin vs carboplatin) and the presence of liver metastases (yes vs no).
The primary end points were changes in PROs per the EORTC QLQ-C30 global health status/QOL scale and overall survival (OS). Secondary end points included other PROs, safety and tolerability, progression-free survival (PFS), overall response rate, and best overall response.
At baseline, the median age in the overall population (n = 267) was 71 years (range, 44-91). Most patients were 65 years or older (73%), male (72%), did not have liver metastases (81%), had an ECOG performance status of 0 (73%), and received cisplatin plus gemcitabine (59%).
What were the additional efficacy and safety data?
Preliminary OS data showed that the median OS values were similar between the 3- and 6 cycle arms, at 18.92 (95% CI, 12.81-not reached [NR]) and 18.86 months (95% CI, 13.93-NR), respectively (HR, 1.15; 95% CI, 0.72-1.86; P = .56). Similarly, the median PFS was 8.0 months (95% CI, 6.70-11.89) vs 9.0 months (95% CI, 6.87-12.71), respectively (HR, 1.053; 95% CI, 0.725-1.527; P = .788).
Responses were also similar between the 2 arms. Response-evaluable patients who received 3 cycles of chemotherapy (n = 95) experienced a complete response (CR) rate of 13% and a partial response (PR) rate of 48%. The respective CR and PR rates in the 6-cycle arm (n = 100) were 13% and 46%.
In terms of safety, grade 1/2 treatment-related adverse effects (TRAEs) occurred at respective rates of 37% and 46% in the 3- and 6-cycle arms. Serious adverse effects (AEs; 35% vs 37%), grade 5 AEs (2% vs 0%), and discontinuation of chemotherapy due to TRAEs (2% vs 10%) were also reported. In the overall population (n = 1197), the most common any-grade TRAEs included anemia (9%), neutropenia (9%), nausea (8%), and fatigue (6%).
“We cannot claim noninferiority [in terms of OS] because of the trial design, [however] OS is still evolving. We will need more data with longer follow-up,” Grande said
Disclosures: Grande received honoraria for speaker engagements, advisory roles, or funding of continuous medical education from AbbVie, Adium, Advanced Accelerator Applications, Astellas, AstraZeneca, AVEO, Bayer, Bristol Myers Squibb, Clovis-Oncology, Dr. Reddy’s Eisai, Esteve, Eusa Pharma, GSK, IMVAX, IPSEN, ITM-Radiopharma, Janssen, Lilly, Merck KGaA, MSD, Novartis, Palex, Pfizer, Raffo, Roche, Rovi, and Tecnofarma. He received research grants from Astellas, AstraZeneca, IPSEN, Merck KGaA, Nanostring Technologies, Pfizer, and Roche. He has leadership roles in ENETS, ESMO, GETNE, Grupo Centro Tumores Genitourinarios, and GUARD consortium. He has stock or ownership interst in Amarin Corp, Bicycle Therapeutics, and Phamamar S.A.
References
Grande E, Hussain S, Climent MA, et al. DISCUS: a phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.Presented at: 2025 ESMO Congress; October 17-25, 2025; Berlin, Germany. Abstract LBA109.
Comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer (DISCUS). ClinicalTrials.gov. Updated March 25, 2025. Accessed October 21, 2025. https://clinicaltrials.gov/study/NCT06892860
NEW YORK — NEW YORK (AP) — If someone left a government job with a black eye, literally, ran a company with shrinking profits, and suddenly had federal investigators crawling over their business, you might say they’re having a bad year.
But most people are not Elon Musk.
The world’s richest man has only gotten richer this year and shareholders at Tesla, his electric car company, may make him wealthier yet by approving a trillion-dollar pay package in a bet he will succeed with new plans for a “robot army” and other technological breakthroughs even as some past promises remain unfulfilled.
“The genius of Elon Musk is keeping investors focused on what the company might look in like 5 or 10 years — while ignoring very near-term challenges,” marvels Garrett Nelson of CFRA Research. Or put more bluntly by Zacks Investment’s Brian Mulberry, “Your average CEO would likely not survive this.”
Musk started out the year with a side hustle — promising to cut $2 trillion in government spending as head of President Donald Trump’s Department of Government Efficiency, before cutting that pledge in half. In the end, DOGE posted only $240 billion in savings, according to its own notoriously unreliable estimates, and it’s not even clear those savings will hold as the Trump administration scrambles to refill many essential jobs DOGE cut that it shouldn’t have.
“There is a pattern of them announcing great big firings, and then turning about and saying, ’No, that’s a mistake,’” said Elaine Kamarck, a Brookings Institute senior fellow who has compiled a list of 17,000 positions being refilled. “They cut without a plan, without regard to function.”
Musk used the same slash-and-burn tactics after he took over Twitter and evidence of that backfiring has emerged this year, too.
In the past two months, he’s settled a pair of lawsuits filed by 2,000 former Twitter employees and executives alleging that they were pushed out under false pretenses or never given severance as promised. The amount the ex-workers got was undisclosed, but if they received even a fraction of the combined $628 million they were demanding, the cost will cut deeply for a company whose advertising has plunged since his takeover.
More bad news for Musk came Wednesday when Tesla announced earnings had plunged 37% in the third quarter. Vehicle sales rose 6% as customers rushed to take advantage of a federal tax credit before it expired last month, but the figure for the full year is expected to drop significantly as car buyers turned off by Musk’s right-wing political stances have boycotted the business.
This time a year ago Musk was telling investors sales could grow 20% to 30%.
The stock fell earlier this year as the bad news piled up. But after Musk appeared in the Oval Office in May for his farewell to DOGE sporting a shiner, it has doubled and is now posting a year-to-date gain of nearly 9% after the close of regular trading Wednesday. His net worth has also jumped — up $62 billion this year to $483 billion, according to Forbes magazine.
Investors are mostly buying Musk’s line that plunging car sales don’t matter as much now because the future of the company lies more with his new driverless robotaxis service, the energy storage business and building robots for the home and factory. To make his task worth while, Tesla’s directors are asking shareholders to sign off on his enormous new pay package at an annual meeting next month.
But there are big questions surrounding these endeavors, particularly the driverless cabs.
Musk’s robotaxis, which began picking up passengers in Austin, Texas, and San Francisco this summer, can’t yet be called driverless because they still require “safety monitors” who are ready to seize control in case something goes wrong, which occasionally happens. One of them drove down the opposing lane, for example.
The robotaxi plans need approval from regulators in various states even as the ones in Washington have swarmed the company.
They’ve opened four investigations into Tesla so far this year, including one into why it hasn’t reported accidents involving its self-driving software quickly to the government as required. Another launched earlier this month is looking into dozens of reported accidents in which Teslas using self-driving software ran red lights and broke other traffic rules, occasionally crashing into other vehicles and causing injuries.
Musk has disappointed before, talking big and missing deadlines repeatedly, only to deliver for shareholders eventually. Tesla investors who held on through a tough 2018 as the company struggled to produce its Model 3 vehicle at a profit, eventually saw their stock soar as sales jumped.
One money manager who rode that earlier surge then bought again earlier this year, says she’s confident Musk’s magic is still there and he can pull off the seemingly impossible again.
“He frequently teeters on the edge of disaster,” said Nancy Tengler in a statement, “and then pulls back just in the nick of time.”
One difference now is most other Tesla investors also believe this and have bought up the stock, leaving little room for error.
Shares of U.S. companies in the S&P 500 index are valued at 24 times what investors expect them to earn next year. By contrast, Tesla is trading at 250 times expected profits, enough to make you believe that Musk, instead of having a very bad year is having a spectacular one.
DURBAN, South Africa — A top executive at Africa’s biggest drug company shared a few home truths with the continent’s health policymakers about the obstacles to local manufacturing at the Conference on Public Health in Africa (CPHIA) 2025.
Aspen Pharmacare’s Dr Stavros Nicolaou blamed regulatory bottlenecks and procurement policies for the failure of drug manufacturers on the continent to realise their potential.
“It is unacceptable for African manufacturers to undergo a six-year [qualification] process before you get to market. We can do this in half the time,” he told a conference plenary session on local manufacturing on Thursday.
He is both Aspen’s group senior executive for strategic trade and chair of the industry body, the Pharmaceutical Manufacturers in South Africa.
It is a myth that African manufacturers are uncompetitive, added Nicolaou. For example, Aspen is active in 55 markets, reaches patients in over 150 countries, and is the global leading supplier of generic anaesthetics outside of the US.
Shift procurement
Nicolaou called for a shift in multilateral procurement, including by Gavi, UNICEF and the Global Fund to Fight Aids, Tuberculosis and Malaria.
He told delegates that the establishment last year of the African Vaccine Manufacturing Accelerator (AVMA) was “a start”, but that the accelerator is “not fit for purpose” in its present form.
AVMA is a financing mechanism set up to raise $1.2 billion for manufacturers over 10 years. Nicolaou told Health Policy Watch that this amount – earmarked for “fill-and-finish” drug manufacturers – was rather modest.
He feels that there is insufficient incentive to spur the growth of the sector, upon which the future expansion of the medical products value chain depends.
“We can’t have African solutions compiled elsewhere and imposed on Africa. It won’t work.”
Pooled procurement of vaccines, therapeutics and diagnostics must be established “with speed”, he said.
‘Nothing has happened’
Nicolaou noted that more than four years had passed and “nothing” had happened since the African Union and the Africa Centres for Disease Control and Prevention (Africa CDC) announced their ambition to ensure the continent manufactures 60% of its vaccine needs by 2040.
The AVMA launch came in the wake of the COVID-19 pandemic, which exposed the continent’s 99% reliance on foreign vaccine manufacturers and how its urgent needs were relegated to the back of the world procurement queue.
Nicolaou also responded to comments by South Africa’s Minister of Science, Technology and Innovation, Dr Blade Nzimande, who gave the session’s keynote address.
South Africa’s Minister of Science, Technology and Innovation, Dr Blade Nzimande
Nzimande called for efforts to “build sovereign capacity” in R&D, science and technology, including across the “whole health manufacturing value chain… be it therapeutic, diagnostic or vaccines we need for our continent”.
He described as “historic” the 60% by 2040 plan to develop tools to secure the continent’s health. He sketched how the initiative sought to expand capacity, implement health standards, and harmonise regulations — all themes elaborated on by other speakers and panellists at the session.
Nzimande toasted the initiative with a glass of water while at the lectern, encouraging his audience to join with applause.
“Government has an important role to play by acquiring locally produced therapeutics, diagnostics and vaccines,” he said.
Serial importer
Nicolaou said he was disappointed that Africa had the highest disease burden yet remained a serial importer and “every year the trade deficit in pharmaceuticals grows”.
South Africa and Egypt have the continent’s largest pharmaceutical markets.
“If you’re talking about security of supply for the continent, South Africa is immensely important. Charity starts at home in that we need to fix our own [national] procurement legislation first,” he said.
“Most of the volumes are procured via the state, and yet we continue to be a serial importer of pharmaceutical products in South Africa. The market is valued at R70-billion (manufacturers’ exit price)… and our trade deficit is more than 50% or around R39-billion.”
There was big potential for local production, yet South Africa continued to import high-volume products like antiretrovirals and vaccines, putting the brakes on local manufacturing development.
“There’s a heavy weighting towards importers, and we now have the data,” he said, citing customs figures, including information on imports from India.
Delegates at CPHIA 2025
Import reliance
“It demonstrates the extent of the problem. So we import significant and vast sums of our antiretrovirals. We have the largest HIV population of any country in the world; 17% of the world’s HIV population; there are about eight million infected people; about 6.6 million on treatment; and yet we continue to import most of our antiretrovirals.”
These imports were growing every year and, apart from antiretrovirals, included other high-volume products such as vaccines, TB medicines, and insulins.
He said this was despite local companies often being price competitive or representing “best value”: an opportunity to grow the local economy through the multiplier effect.
He proposed a three-point plan to remedy matters. First, the introduction of a priority review and parallel submission to expedite the licensing of medicines. The review of drugs by the national regulator should happen at the same time as the World Health Organisation’s review, instead of sequentially, which can add two to three years of costly delays.
Second, increase Gavi subsidies for the local production of vaccines to stimulate the market.
Third, establish a pool for procurement for the entire continent — as was successfully done during COVID-19 — to unlock economies of scale.
African Union leaders signed an agreement with Rwanda’s Ministry of Health to establish the African Medicines Agency’s (AMA) headquarters in the capital, Kigali, in June 2023. Once operational, AMA will harmonise drug regulation across the continent.
Also addressing the plenary, Nhlanhla Msomi, president of AfricaBio, called for a compact with the manufacturing industry to localise innovation.
However, Nicolaou said that it was premature to expect expansion of the value chain.
It was first necessary to support African manufacturers with fill-and-finish products to allow them to develop capacity and grow volume. In time, they could then invest in extending the value chain.
“Unless you start getting orders and you start succeeding in fill-and-finish first, companies are not going to backwardly integrate into drug [active] substance development,” he said.
Nicolaou said progress was not happening fast enough, and this was sapping momentum to achieve the “60% by 2040” aim.
“There’s a domestic issue to sort out, and then a continent,” he said.
Also at the plenary session, Dr Serge Blaise Emaleu, a global and public health and infectious diseases expert, said sustainable development could shift Africa from being an epicentre of disease to the centre of innovation.
Local manufacture was the “backbone of a sovereign health ecosystem”, but he cautioned that the commitment by African leaders to promote manufacture and invest in research “must be backed by financing” and that governance and leadership were required, and these things must be “moving in lockstep”.
Emaleu identified five interconnected pillars upon which Africa’s R&D self-reliance must be built: linking science to production; funding for research and development; investing in human resources; *building infrastructure and technology, and finally a regulatory framework to safeguard and sustain momentum.
Image Credits: Africa CDC, Rwanda Ministry of Health.
Combat the infodemic in health information and support health policy reporting from the global South. Our growing network of journalists in Africa, Asia, Geneva and New York connect the dots between regional realities and the big global debates, with evidence-based, open access news and analysis. To make a personal or organisational contribution click here on PayPal.
Sensor specialist HENSOLDT is adjusting its guidance for the 2025 financial year following recent and further foreseeable order intake. The company now expects a significantly increased book-to-bill ratio of 1.6x to 1.9x, whereas previous expectations were approximately 1.2x. In addition, the expected revenue is specified at approximately 2,500 million euro (previously: range of 2,500–2,600 million Euro) and the adjusted EBITDA margin at 18% or higher (previously: approximately 18%). At the same time, the company confirms its medium-term guidance and revenue ambition for 2030.
Following the German government’s decision to initiate further procurement in numerous defence programmes due to the continuing high threat level, this is now increasingly reflected in concrete orders. With its solutions meeting current and future security requirements, HENSOLDT is benefiting considerably from this. As a result, the recent orders will push the book-to-bill ratio for 2025 above the previously expected 1.2x.
The increasing order intake also comes with a clear mandate: industrial scaling of its programmes remains a top priority for HENSOLDT. The company is expanding its capacities through automation measures, a new logistics centre and a new building in Oberkochen. In addition, comprehensive transformation initiatives in the areas of operations, engineering and supply chain are driving efficiency, flexibility and resilience. Despite the high complexity of the ramp-up, HENSOLDT is well on track here. At the same time, profitability remains secure: the specification in the EBITDA margin clearly shows that HENSOLDT is capable of efficiently execute the increased orders and operate successfully in economic terms.
Oliver Dörre, CEO of HENSOLDT, explains: “The fact that Germany is investing strongly in its own security due to the current security situation and that this political will is now being reflected in concrete orders is an important step towards genuine defence capability. Thanks to innovative technologies and the consistent expansion of our industrial capacity, we are well positioned to make an important contribution to this. This demonstrates HENSOLDT’s ability to reliably deliver complex products and solutions even in the face of significantly increasing demand.”
Christian Ladurner, CFO of HENSOLDT, says: “The raise of our book-to-bill ratio and the specification of the adjusted EBITDA margin shows that HENSOLDT is not only growing but also continuing to operate profitably. Through targeted investments in capacity and processes, we are securing our delivery capability and sustainable growth. At the same time, our company’s operational strength forms the basis for consistently implementing our strategic priorities.”
Redwood Materials plans to meet the AI-fueled demand for energy with recycled electric-car batteries
J.B. Straubel is a former Tesla executive who left to focus on his energy startup, Redwood Materials.
The battery-recycling company founded by an ex-Tesla Inc. executive can count a high-profile artificial-intelligence company among investors in its latest funding round.
Redwood Materials said Thursday it had raised $350 million in a round led by the venture-capital firm Eclipse and Nvidia Corp.’s (NVDA) venture-capital arm, NVentures. Nvidia’s contribution to the round was not disclosed, and a representative did not immediately return a request for comment.
The fundraise comes as major AI players are scrambling to meet their power needs and as the U.S. is facing difficulties building out domestic mineral-supply chains. Currently, China is – by far – the dominant force in the global supply chains for cobalt, nickel and other minerals. And rising tensions between China and the U.S. have stoked worries that some companies, including carmakers, may get cut off from lithium-ion batteries and battery materials.
Don’t miss: Quantum stocks are rising. Why they may be the Trump White House’s next investment.
“This is a pivotal time for both Redwood and the United States, as curtailment in international supplies overlaps with intense domestic demand growth for these same materials and energy products,” the company said in a statement.
Redwood said it would use the new cash to expand its growing energy-storage business, which it launched in June under the name Redwood Energy and which seeks to meet the quickly escalating demand for energy needed for AI data centers. By 2030, global power demand from data centers is set to grow 165% compared with 2023, according to Goldman Sachs.
“AI is several things. AI is energy, AI is chips, the models and the application,” Nvidia CEO Jensen Huang said in a recent interview with CNBC’s “Squawk Box.” “And we need more energy.”
Redwood believes it already has the supply chains necessary to match its ambitions. The company has said it receives batteries equivalent to 250,000 electric vehicles annually, or about 90% of all lithium-ion batteries and battery materials recycled in North America.
Redwood’s core business involves recycling scrap from consumer electronics and batteries, extracting minerals like cobalt and nickel and selling those components back to partners and battery suppliers, including Toyota Motor Corp (JP:7203).
Now it says it won’t take battery packs apart immediately, instead diverting what power remains to fuel low-cost, large-scale energy-storage systems. Once that energy is fully drained, the batteries are sent to be scrapped for parts as usual.
“Low-cost, large-scale battery energy storage has emerged as the most immediate and scalable solution to enable AI factory deployment and unlock stranded grid and generation capacity,” Redwood said in a statement.
Redwood was founded in 2017 by J.B. Straubel, a Tesla (TSLA) co-founder and executive who left the company to scale his startup. Straubel’s former employer is also seeking to meet growing energy demand.
See more: This underrated Tesla business deserves more attention – and it’s not AI
Beyond expanding its energy business, Redwood said it will also use the new capital to expand its refining and material-production capacity and build out its engineering and operations teams. The company was valued at $1 billion in late 2023, following its previous fundraising round, according to TechCrunch.
-William Gavin
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Industrial conglomerate Dover reported better-than-expected third-quarter profits Thursday and gave skeptical investors plenty to like, sending the stock up more than 6%. Revenue rose 4.7% year over year to $2.08 billion, missing the consensus of $2.11 billion, according to estimates compiled by LSEG. Adjusted earnings per share (EPS) in the three months ended Sept. 30 totaled $2.62, easily topping the $2.51 consensus, LSEG data showed. On an annual basis, adjusted EPS rose 15.4%. Shares of Dover climbed about 6.8%, to roughly $179 apiece, in Thursday’s session. That has the stock on pace for its second-best day of the year — behind only a 9.7% surge in the everything rally of April 9, when President Donald Trump paused most of his “reciprocal tariffs.” Dover’s stock desperately needed a boost. It entered Thursday’s session down more than 10% this year, trailing both the S & P 500 and the index’s industrial sector. Why we own it We own Dover as an industrial turnaround story with exposure to mega-themes, most notably the data center buildout to support artificial intelligence computing. The company’s key products for data centers are thermal connectors and heat exchangers. Dover’s business serving the biopharma industry is another attractive area. Dover’s active portfolio management and commitment to capital returns sweeten the investment case. Competitors : Ingersoll Rand , IDEX Corp ., Snap-On , Veralto , among others Most recent buy: July 30, 2025 Initiated : May 28, 2024 Bottom line Things are starting to look up. Coming into Thursday’s third-quarter release, Dover had struggled to gain traction this year in a market largely fueled by artificial intelligence excitement, a theme that lifted industrial players like Vertiv and Caterpillar , along with fellow Club names GE Vernova and Eaton , to impressive heights. While Dover has ties to the data center and the AI infrastructure buildout, it’s not as obvious a beneficiary as other industrial players thanks to a wide-ranging business portfolio that serves so many other markets — like can-making, digital printing, vehicle repair, and grocery store refrigeration, to name a few. The latter two businesses, in particular, have been major drags on growth this year, further complicating the Dover investment case. In search of cleaner growth stories within industrials, investors looked past Dover. They’re taking a closer look on Thursday. And rightfully so, considering the company painted an upbeat picture of its ability to benefit from lucrative trends, including AI, demonstrated strong profitability improvements and raised its full-year earnings guidance, and indicated that its sizable cash pile could soon be put to productive uses. “I thought it was a travesty that [the stock] fell this much,” but our patience is finally being rewarded, Jim Cramer said Thursday. DOV 1Y mountain Dover 1-year return We’re reiterating our buy-equivalent 1 rating and price target of $210 on the stock. Even with the strong move Thursday, shares are trading at just over 17 times next year’s consensus earnings. That’s a steep discount to a popular exchange-traded fund of industrial companies, known as the XLI , which trades at roughly 23 times 2026 earnings. Commentary At a very high level, Dover executives nailed the messaging on the company’s exposure to growth markets like data centers, the AI-related rise in electricity consumption, and growing demand for liquified natural gas (LNG) exports. Shifts within the pharmaceutical industry toward more complex biologic therapeutics and the adoption of safer, more efficient single-use components in manufacturing also benefit some of Dover’s businesses. On its earnings slideshow, the company made clear that more than 20% of its annualized revenue is now tied to “secular growth end markets.” And on the conference call, CEO Richard Tobin said these markets are also helping to drive margin expansion. Tobin also offered a detailed explanation of Dover’s ties to these compelling themes, going deeper than its business of selling thermal connectors and heat exchangers to cool server racks and data centers, which has been well-publicized up to this point. For example, Tobin mentioned how its OPW Clean Energy Solutions subsidiary supplies components to gas and steam turbines — a red-hot market, as GE Vernova has made clear — as well as specialized piping used to liquify natural gas, making it easier to ship overseas. LNG export capacity in the U.S. could more than double by 2029, the Energy Information Administration said last week . Tobin also explained how the recently acquired Sikora boosted its exposure to electricity infrastructure because Sikora’s measurement and control technology is used on high-voltage, polymer-coated wires and cables. After being acquired in June, Sikora has “really done fantastically, significantly better than our deal model would’ve incorporated for the base year,” added Tobin. Against that backdrop, Dover’s Pumps & Process Solutions segment — home to single-use biopharma components, thermal connectors, and Sikora — was the standout in the third quarter. Revenues rose 16.6% year over year, bookings grew by 14%, and its adjusted EBITDA margin came in at a better-than-expected 33.2%. Short for earnings before interest, taxes, depreciation, and amortization, EBITDA is a gauge of operating profitability. With Dover making productivity improvements and cost-cutting measures a focus across the company, it was encouraging to see all five segments beat the FactSet consensus for adjusted EBITDA in the quarter. Tobin’s commentary on 2026 was also a highlight. “I’m not aware of any business within the portfolio that’s forecasting down revenue for next year,” he said, adding that it’s “probably the first time” in a couple of years that Dover is not expecting at least one unit to see a cyclical decline. This includes its grocery refrigeration business, where shipments of door cases across the industry are at a 20-year low, Tobin said, as tariff uncertainty caused customers to pause maintenance and replacement spending. “These projects cannot be delayed indefinitely,” Tobin said. And encouragingly, we saw a material acceleration in booking rates in the quarter, which signals volume improvement moving forward.” This business is housed within its Climate & Sustainability Technologies segment, which saw 25% growth in year-over-year bookings in the quarter. The slowdown in refrigeration — not something Dover anticipated at the start of the year — has been a drag on organic growth in 2025 of roughly 1.5 to 2 percentage points, Tobin said. In dollar terms, that amounts to a $140 million to $150 million headwind. “Do we get it all back next year? We’ll see, but I think we’re going to get a significant portion of it back if the Q4 trajectory holds as we go through the end of the year,” Tobin said. Another major problem child in 2025 has been the vehicle service market, contained within Dover’s Engineered Products segment. This includes products like the vehicle lifts and wheel aligners used at the auto repair shop. Encouragingly, Dover is expecting to see a quarter-over-quarter improvement in the fourth quarter. Dover also delivered with its commentary on the company’s cash pile, which grew considerably last year when it sold off its subsidiary that made trash trucks and compactors for $2 billion . Asked directly by JPMorgan’s Steve Tusa whether Dover is considering buying back stock given its depressed valuation, Tobin said: “If you go back and look in the transcript, you’ll see the corporate speak for, ‘We think our shares are cheap, and we’re likely to intervene.'” In August, Dover announced a $500 million share repurchase program, but at the end of September, the company had only spent $40.7 million repurchasing common stock during the first nine months of the year, according to a securities filing Thursday . As for whether Dover might use any of its cash to buy additional companies, Tobin said Dover is “being selective as usual.” However, he continued, “We’ve got enough in the pipeline that I would expect that we’d close on a couple of things over the next 12 months.” Earlier on the conference call, Tobin noted that the majority of Dover’s acquisitions in the past five years have been geared toward the aforementioned faster-growing markets, and he said they “remain top priorities for continued investment.” In the coming quarters, one more potential growth driver for Dover is the pharmaceutical companies that plan to build manufacturing plants in the U.S. to avoid Trump’s tariffs. Not only does Dover sell the single-use pumps and connectors used in drug production, its Imaging & Identification segment sells serialization and traceability software through its Systech subsidiary, acquired in 2020 . Dover expects the entire segment to continue its “long-term steady growth trajectory,” while calling out “additional upside from serialization software.” The serialization software business is “levered almost exclusively to pharma,” Tobin said later on the call. “So, as pharma builds out production lines, that’s when we sell the software and the recurring revenue associated with it. I think that everybody is pretty well aware of what’s going on in … incentivized reshoring of pharma. And I think that we’ll get our fair share of that.” Guidance Here’s Dover’s revised earnings guidance for the full year: EPS in the range of $9.50 to $9.60. The midpoint of $9.55 is ahead of the $9.48 consensus, according to FactSet. That implies fourth-quarter EPS between $2.40 and $2.50. Ahead of Thursday’s results, the FactSet consensus for the fourth quarter stood at $2.49. It continues to forecast full-year 2025 revenue growth in the 4% to 6% range. (Jim Cramer’s Charitable Trust is long DOV. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Apple to appeal CAT ruling, claims app economy is competitive
Ruling on first tech giant trial boosts UK ‘class action’ regime
Other tech giants like Google face similar lawsuits in UK
LONDON, Oct 23 (Reuters) – Apple (AAPL.O), opens new tab abused its dominant position by charging app developers unfair commissions, a London tribunal ruled on Thursday, in a blow which could leave the U.S. tech company on the hook for hundreds of millions of pounds in damages.
The Competition Appeal Tribunal (CAT) ruled against Apple after a trial of the lawsuit, which was brought on behalf of millions of iPhone and iPad users in the United Kingdom.
Sign up here.
The CAT ruled that Apple had abused its dominant position from October 2015 until the end of 2020 by shutting out competition in the app distribution market and by “charging excessive and unfair prices” as commission to developers.
Apple – which has faced mounting pressure from regulators in the U.S. and Europe over the fees it charges developers – said it would appeal against the ruling, which it said “takes a flawed view of the thriving and competitive app economy”.
The case had been valued at around 1.5 billion pounds ($2 billion) by those who brought it. A hearing next month will decide how damages are calculated and Apple’s application for permission to appeal.
Thursday’s ruling comes after Apple was hit with a complaint to European antitrust regulators over the terms and conditions of its App Store under rules aimed at reining in Big Tech.
LANDMARK MASS LAWSUIT
Rachael Kent, the British academic who brought the case, argued Apple had made “exorbitant profits” by excluding all competition for the distribution of apps and in-app purchases.
Her lawyers argued at the start of the trial in January that Apple’s “100% monopoly position” allowed it to impose restrictive terms and excessive commissions on app developers, which Apple denied.
The CAT said in its ruling that developers were overcharged by the difference between a 17.5% commission for app purchases and the commission Apple charged, which Kent’s lawyers said was usually 30%. The CAT also ruled that app developers passed on 50% of the overcharge to consumers.
“This ruling overlooks how the App Store helps developers succeed and gives consumers a safe, trusted place to discover apps and securely make payments,” an Apple spokesperson said.
BOOST FOR UK’S ‘CLASS ACTION’ REGIME
The case was the first mass lawsuit against a tech giant to come to trial under Britain’s fledgling class action-style regime, which this year reached its 10th anniversary and has seen several multi-billion-pound cases certified for trial but with limited success for consumers so far.
There are, however, many other cases waiting in the wings, including one against Google (GOOGL.O), opens new tab over the commission it charges app developers for access to its Play Store.
That case is due to begin in October 2026 and will be heard alongside a similar claim by Epic Games, which is engaged in parallel litigation with Apple in the U.S.
Fellow tech giants including Amazon and Microsoft are also facing sizeable claims at the CAT.
Kent said in a statement that the ruling shows Britain’s collective action regime is working and “sends a clear message: no company, however wealthy or powerful, is above the law”.
($1 = 0.7451 pounds)
Reporting by Sam Tobin; editing by William James and Keith Weir
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Calvin Klein Inc. today announces the U.S. launch of Re-Calvin, a new take-back program designed to make it easy for customers to responsibly part with their pre-loved items.
Developed in partnership with Trove, the leader in branded resale and customer trade-in, and Debrand, a comprehensive sortation and circular logistics partner, Re-Calvin is a free service from Calvin Klein that gives U.S. customers a simple, accessible way to extend the useful life of clothing, shoes and accessories from any brand through donation, recycling, downcycling or, when necessary, responsible disposal that is converted from waste to energy. Re-Calvin also accepts intimates such as bras, swimwear and underwear – a category often excluded from circularity programs.
“As Calvin Klein continues its sustainability journey, we are proud to introduce a program that makes circularity more accessible for our customers and delivers alternative uses for pre-loved items,” said David Savman, Global Brand President, Calvin Klein. “It was important that we partner with experts with a proven ability to build and scale programs that handle a wide range of products andcategories, making it easier than ever for customers to responsibly extend the life of their items.”
How It Works
Customers in the United States can visit calvinklein.us/re-calvin to print a free shipping label and send in items from any brand. Once received, each package is processed and routed according to Calvin Klein’s diligent, established standards:
Reuse: Items in good condition are donated or sent to secondhand distribution partners.
Recycle / Downcycle: Items that cannot be reused, including intimates, are recycled into new fibers whenever possible, or downcycled into materials such as insulation or padding.
Responsible Disposal: As a final step, if no reuse, recycling or downcycling option is available, items are to be converted from waste to energy or alternative fuel conversion.
Only items suitable for a new owner are directed to reuse. Garments with significant wear, damage, heavy stains and all intimates are directed to end-of-use streams, including recycling, downcycling and responsible disposal. Customers receive an email update after their parcel is processed, detailing how their items were routed, ensuring transparency throughout the process.
Powered by Trove’s Takeback Plug-In
Re-Calvin is powered by Trove’s new Takeback Plug-In, which enables Calvin Klein to seamlessly manage item intake, routing and transparency at scale. The plug-in integrates directly into Calvin Klein’s existing U.S. website, enabling the brand to operate a multi-brand takeback program that includes complex categories such as intimates.
The Takeback Plug-in expands Trove’s suite of circular solutions, which also includes the Resale Plug-in, Trade-in Plug-in and a range of API integration options. Together, these tools give brands the flexibility to build customized circular programs that meet their unique needs.
“Re-Calvin marks the first implementation of Trove’s new Takeback Plug-In,” said Terry Boyle, CEO of Trove. “With this launch, Calvin Klein is showing how technology can make responsible choices simple for every customer, accepting items from any brand and across all categories, including intimates, to help keep more textiles in circulation.”
By accepting items from any brand and across all categories, Re-Calvin reflects Calvin Klein, Trove and Debrand’s shared belief that every item should have as many chances as possible to find a second life.
An autistic man who was let go as an unpaid shelf stacker at a Waitrose supermarket despite volunteering there for years has been offered a job at Asda.
Tom Boyd, 28, had worked in the Cheadle Hulme Waitrose store since 2021 with a support worker, as his mother, Frances Boyd, said the role gave her son “a sense of purpose and belonging”.
In a Facebook post last Friday, she wrote that her “autistic son has been treated so unfairly, and we feel deeply let down” by Waitrose. She said the supermarket declined to give him a paid job despite him offering more than 600 hours to the store “purely because he wanted to belong, contribute, and make a difference”, and that he was a well-liked member of the team by his co-workers.
Boyd added that they had only asked for a few hours of paid work “not as charity, but as recognition for all the time, effort, and heart” Tom had given to the store, and that she and her family were “shocked by how dismissive and cold” the management’s response was, and that Tom was asked not to return.
The post also claimed that Waitrose had not made any reasonable adjustments for Tom, who has limited communication skills, despite it being mandated by the Equality Act 2010, and that he received “no apology, no thanks, and no recognition for his commitment. Just silence.”
The post led to an outpouring of support for Tom, with Boyd telling the BBC on Thursday that she had been “overwhelmed” by people’s responses and that her son had been offered a job by another supermarket.
“We’ve had some great news – Asda have offered him two five-hour paid shifts a week,” Boyd said. “It’s overwhelming and they are flexible to say if at any time he is struggling they are fine. How amazing that a company could do this.”
As well as support, Boyd’s Facebook post also led to intense criticism being directed towards Waitrose for its handling of the situation, with some customers claiming on social media that they would no longer visit the store.
The mayor of Greater Manchester, Andy Burnham, decried the company’s “truly terrible” treatment of Tom in a post on X.
After the backlash, Waitrose offered Boyd his job back in a paid capacity, but it is understood this offer was declined.
Burnham also pledged to support Boyd and others like him, saying that the Greater Manchester Combined Authority “would encourage all employers, including Waitrose, to sign up to our brand new Bee Neuroinclusive code of practice”, a guide for how companies should support neurodivergent employees. He offered Boyd’s mother the chance to be an ambassador for campaign, which she accepted.
skip past newsletter promotion
after newsletter promotion
Speaking on Wednesday, a Waitrose spokesperson said the company was “well experienced in making reasonable adjustments to help people succeed at work”, adding: “We are sorry to hear of Tom’s story and whilst we cannot comment on individual cases, we are investigating as a priority.”
A spokesperson for Asda said the company “has a supported internship programme and partnership with DFN Project Search – a national charity for young people with autism or a learning disability – through which we have welcomed over 30 talented new colleagues into roles across our stores”.
“We have seen the positive impact this has for the individuals who join and for our colleagues and customers too. So when we heard about Tom and his desire to find meaningful work, we knew he’d be a fantastic fit and we are delighted to offer him a role at his local store,” they added.